ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Press
August 6, 2024
06 Mar 2024

Idag inleds utnyttjandeperioden för Acarix teckningsoptioner av serie 2024:U1 (TO2)

Utnyttjandeperioden för de teckningsoptioner av serie 2024:U1 (TO2) (”Teckningsoptioner”) som emitterades i samband med Acarix AB:s (”A...
Continue reading
author-avatar acarix
Press
August 6, 2024
06 Mar 2024

The exercise period for Acarix warrants of series 2024:U1 (TO2) begins today

The exercise period for the warrants of series 2024:U1 (TO2) (the "Warrants") issued in connection with Acarix AB ("Acar...
Continue reading
author-avatar acarix
Press
August 6, 2024
21 Feb 2024

Kommuniké från extra bolagsstämma i Acarix

Extra bolagsstämma i Acarix AB ("Bolaget") hölls idag den 21 februari 2024 varvid aktieägarna fattade följande beslut. Godkän...
Continue reading
author-avatar acarix
0 comments
Press
February 21, 2024
21 Feb 2024

Announcement from Acarix’s extra general meeting

The extra general meeting of Acarix AB (the "Company") was held today on 21 February 2024 and the following resolution was pa...
Continue reading
author-avatar acarix
Press
August 6, 2024
15 Feb 2024

Acarix AB (publ) publicerar Bokslutskommuniké 2023

Fokus mot USA och hållbar tillväxt Som nyutnämnd VD är jag hedrad att få leda Acarix och dela en del av våra vision för framtiden. Foku...
Continue reading
author-avatar acarix
Press
August 6, 2024
15 Feb 2024

Acarix AB (publ) publishes Year-End Report 2023

Embarking on a new journey with focus on sustainable growth As the newly appointed CEO of Acarix, I am honored to be on board and share...
Continue reading
author-avatar acarix
Press
August 6, 2024
01 Feb 2024

KALLELSE TILL EXTRA BOLAGSSTÄMMA I ACARIX AB

Aktieägarna i Acarix AB, org.nr 559009-0667 ("Bolaget"), kallas härmed till extra bolagsstämma onsdagen den 21 februari 2024 ...
Continue reading
author-avatar acarix
Press
August 6, 2024
01 Feb 2024

NOTICE OF EXTRA GENERAL MEETING IN ACARIX AB

The shareholders of Acarix AB, reg. no. 559009-0667 (the "Company"), are hereby invited to the extra general meeting on Wedne...
Continue reading
author-avatar acarix
Press
August 6, 2024
30 Nov 2023

Acarix changes Certified Adviser to Carnegie Investment Bank AB (publ)

Acarix, a leader in advanced acoustic-based cardiac diagnostics, today announces a change of Certified Adviser from Erik Penser Bank AB...
Continue reading
author-avatar acarix
Press
August 6, 2024
30 Nov 2023

Acarix byter Certified Adviser till Carnegie Investment Bank AB (publ)

Acarix, ledande inom avancerad akustisk hjärtdiagnostik, meddelar idag att man byter Certified Adviser från Erik Penser Bank AB till Ca...
Continue reading
author-avatar acarix
Press
August 6, 2024
16 Nov 2023

ACARIX CARRIES OUT A DIRECTED ISSUE TO GUARANTORS FOLLOWING THE COMPLETED RIGHTS ISSUE

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG ...
Continue reading
author-avatar acarix
Press
August 6, 2024
16 Nov 2023

ACARIX GENOMFÖR RIKTAD NYEMISSION TILL GARANTER EFTER DEN GENOMFÖRDA FÖRETRÄDESEMISSIONEN

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONG...
Continue reading
  • ‹
  • 1
  • 2
  • 3
  • 4
  • ›
  • »
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
[email protected]

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V5

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.